Galactomannan antigen and Aspergillus antibody responses in a transplant recipient with multiple invasive fungal infections

References

1. Antinori S., Corbellino M., Meroni L., Resta F., Sollima S., Tonolini M., Tortorano A.M., Milazzo L., Bello L. other authors.( 2013). Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect 66:218–238 [CrossRef]
   [Google Scholar]
2. Bitar D., Lortholary O., Le Strat Y., Nicolau J., Coignard B., Tattevin P., Che D., Dromer F. ( 2014). Population‐based analysis of invasive fungal infections, France, 2001–2010. Emerg Infect Dis 20:1163–1169 [CrossRef]
   [Google Scholar]
3. Boutboul F., Alberti C., Leblanc T., Sulahian A., Gluckman E., Derouin F., Ribaud P. ( 2002). Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 34:939–943 [CrossRef]
   [Google Scholar]
4. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Pappas P.G., Maertens J., Lortholary O. other authors.( 2008). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821 [CrossRef]
   [Google Scholar]
5. Herbrecht R., Letscher‐Bru V., Oprea C., Lioure B., Waller J., Campos F., Villard O., Liu K‐L., Natarajan‐Amé S. other authors.( 2002). Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20:1898–1906 [CrossRef]
   [Google Scholar]
6. Kume H., Yamazaki T., Togano T., Abe M., Tanuma H., Kawana S., Okudaira M. ( 2011). Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan . Med Mycol J 52:117–127 [CrossRef]
   [Google Scholar]
7. Maertens J., Verhaegen J., Lagrou K., Van Eldere J., Boogaerts M. ( 2001). Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604–1610 [CrossRef]
   [Google Scholar]
8. Mennink‐Kersten M.A.S.H., Donnelly J.P., Verweij P.E. ( 2004). Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4:349–357 [CrossRef]
   [Google Scholar]
9. Miceli M.H., Grazziutti M.L., Woods G., Zhao W., Kocoglu M.H., Barlogie B., Anaissie E. ( 2008). Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 46:1412–1422 [CrossRef]
   [Google Scholar]
10. Neofytos D., Fishman J.A., Horn D., Anaissie E., Chang C‐H., Olyaei A., Pfaller M., Steinbach W.J., Webster K.M., Marr K.A. ( 2010). Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 12:220–229 [CrossRef]
    [Google Scholar]
11. Park S.H., Choi S‐M., Lee D‐G., Choi J‐H., Kim S‐H., Kwon J‐C., Yoo J‐H., Kim H‐J., Lee S. other authors.( 2011). Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses 54:523–530 [CrossRef]
    [Google Scholar]
12. Penack O., Rempf P., Graf B., Blau I.W., Thiel E. ( 2008). Aspergillus galactomannan testing in patients with long‐term neutropenia: implications for clinical management. Ann Oncol ESMO 19:984–989 [CrossRef]
    [Google Scholar]
13. Persat F. ( 2012). [Aspergillus serology, from yesterday to today for tomorrow]. J Mycol Med 22:72–82 (in French) [CrossRef]
    [Google Scholar]
14. Piens M.A., Thiébaut A., Bilger K., De Monbrison F., Michallet M., Picot S. ( 2004). Intérêt de la détection d’antigène aspergillaire dans le liquide céphalo‐rachidien en cas de suspicion d’aspergillose cérébrale. J Mycol Med 14:28–33
    [Google Scholar]
15. Sendid B., Poirot J.L., Tabouret M., Bonnin A., Caillot D., Camus D., Poulain D. ( 2002). Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 51:433–442
    [Google Scholar]
16. Sheppard D.C., Marr K.A., Fredricks D.N., Chiang L.Y., Doedt T., Filler S.G. ( 2006). Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. Clin Microbiol Infect 12:376–380 [CrossRef]
    [Google Scholar]
17. Verweij P.E. ( 2009). Galactomannan and anti‐Aspergillus antibodies detection for the diagnosis of invasive aspergillosis. In Aspergillus fumigatus and Aspergillosis Latgé J P, Steinbach W J. Washington, DC: ASM Press;
    [Google Scholar]
18. Woods G., Miceli M.H., Grazziutti M.L., Zhao W., Barlogie B., Anaissie E. ( 2007). Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110:830–834 [CrossRef]
    [Google Scholar]